- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07569081
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (ATLAS)
A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants With VEXAS Syndrome
This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 2. fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: US GSK Clinical Trials Call Center
- Telefonszám: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: EU GSK Clinical Trials Call Center
- Telefonszám: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Tanulmányi helyek
-
-
-
Salzburg, Ausztria, A-5020
- GSK Investigational Site
-
Kapcsolatba lépni:
- US GSK Clinical Trials Call Center
- Telefonszám: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kapcsolatba lépni:
- EU GSK Clinical Trials Call Centre
- Telefonszám: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kutatásvezető:
- Thomas Melchardt
-
-
-
-
Texas
-
Houston, Texas, Egyesült Államok, 77054
- GSK Investigational Site
-
Kutatásvezető:
- Michelle Eisenberg
-
Kapcsolatba lépni:
- US GSK Clinical Trials Call Center
- Telefonszám: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kapcsolatba lépni:
- EU GSK Clinical Trials Call Centre
- Telefonszám: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Tokyo, Japán, 113-8677
- GSK Investigational Site
-
Kapcsolatba lépni:
- US GSK Clinical Trials Call Center
- Telefonszám: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kapcsolatba lépni:
- EU GSK Clinical Trials Call Centre
- Telefonszám: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kutatásvezető:
- FangYi Chen
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
-
Age greater than equal to (>=)18 years OR of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the Informed Consent Form.
-
Confirmed diagnosis of clinical VEXAS defined by:
- Documented evidence of a canonical, pathogenic Ubiquitin-like modifier activating enzyme 1 (UBA1) mutation
- Inflammatory manifestations: current or documented past involvement within 6 months of at least one organ system
-
Receiving glucocorticoid (GC) treatment (prednisone/prednisolone) for >=4 consecutive weeks for >=10 days prior to randomization.
-
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- Is a Participant of non-childbearing potential (PONCBP) OR
- Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective
-
Is capable of giving signed informed consent including compliance with the requirements and restrictions
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at the time of screening.
-
Has adequate organ function
Exclusion Criteria:
-
More than 1 prior admission to an intensive care unit due to a VEXAS flare within the 6 months prior to randomization.
-
History of severe corticosteroid toxicity: uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), psychiatric, osteoporosis/osteomalacia, glaucoma, corneal ulcers/injuries, nausea or vomiting or gastrointestinal disease.
-
High risk/very high risk Myelodysplastic syndrome (MDS), according to the Revised International Prognostic Scoring System (IPSS-R) with overall risk score >3.5.
-
Peripheral blood blast counts >=10%.
-
Multiple myeloma (all stages) and other active plasma cell dyscrasias requiring treatment.
-
Malignancy (except disease under study including Lower-risk myelodysplastic syndrome [LR-MDS]) that has progressed or required active treatment within the past (24 months) except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas).
-
Uncontrolled intercurrent illness within 12 weeks prior to initiation of momelotinib.
-
Ongoing adverse reaction(s) from prior therapy that have not recovered to Grade <=1 per NCI CTCAE v6.0 or to the Baseline status preceding prior therapy
-
Psychiatric illness, social situation, or any other condition that would limit informed consent and/or compliance with trial requirements or may interfere with the interpretation of study results, as judged by Investigator or Sponsor.
-
Has any clinically significant gastrointestinal conditions or abnormalities that may alter absorption or swallowing
-
Known contraindication or hypersensitivity to momelotinib and its metabolites, or any of their excipients.
-
Presence of peripheral neuropathy >=Grade 2 per NCI CTCAE v6.0.
-
Known history of disseminated mycobacterial infection.
-
Positive status for human immunodeficiency virus (HIV).
-
Positive QuantiFERON (or other interferon gamma release assay) during Screening.
-
Unable to receive any Pneumocystis jiroveci pneumonia (PJP) medical prophylaxis
-
Known clinically significant anemia due to iron, vitamin B12 or folate deficiencies, or autoimmune or hereditary hemolytic anemia, gastrointestinal bleeding, or thalassemia.
-
More than 1 prior line of VEXAS directed therapy before or after VEXAS diagnosis or other medical condition.
-
Use of the following treatments within the noted time periods referenced from date of randomization:
- VEXAS-directed therapies (washout period) up to 5 half-lives or up 14 days if half-life is <3 days
- Other non-GC anti-inflammatory therapies: for non-biologics): 14 days or five half-lives, whichever is longer; for biologics): 28 days or two half-lives whichever is longer.
- Hematologic support therapy (e.g., Erythropoiesis-stimulating agents [ESAs], danazol, luspatercept, Granulocyte-Colony Stimulating Factor [G-CSF]): 4 weeks
- Cell-depleting therapies such as anti-CD20 (rituximab): 12 months
- Investigational agent from a class not otherwise specified: 5 half-lives or 60 days, whichever is longer
-
GC use for conditions other than VEXAS, which would interfere with adherence to the fixed GC taper regimen and/or to assessment of efficacy.
-
Chronic use of systemic corticosteroids for >4 years or inability to withdraw corticosteroid treatment
-
Planned allogeneic Hematopoietic stem cell transplantation (HSCT) for MDS or VEXAS, within 1 year.
-
Any major surgery within 28 days prior to randomization.
-
Prior allogeneic/autologous stem cell transplant or solid organ transplant (other than corneal).
-
Presence of peripheral neuropathy >=Grade 2 per NCI CTCAE v6.0.
-
Hepatitis B or C active infection, unless protocol defined criteria are met.
-
Any of the following conditions within 6 months prior to randomization:
- Unstable angina pectoris
- Symptomatic congestive heart failure
- Uncontrolled cardiac arrhythmia
- QTc >450 millisecond (msec) or QTc >480 msec for participants with bundle branch block.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Momelotinib Dose level 1 + Glucocorticoids
Participants will receive momelotinib at dose level 1 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3. |
Momelotinib will be administered
Más nevek:
Glucocorticoids (prednisone or prednisolone) will be administered |
|
Kísérleti: Momelotinib Dose level 2 + Glucocorticoids
Participants will receive momelotinib at dose level 2 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3 |
Momelotinib will be administered
Más nevek:
Glucocorticoids (prednisone or prednisolone) will be administered |
|
Placebo Comparator: Placebo + Glucocorticoids
Participants will receive momelotinib matched placebo along with glucocorticoids as a background therapy(prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3 |
Placebo will be administered Glucocorticoids (prednisone or prednisolone) will be administered |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
ORR (Objective response rate) at Week 26
Időkeret: At Week 26
|
ORR is defined as the proportion of participants who have achieved complete response (CR) or partial response (PR) during the 26-week Primary Treatment Period. |
At Week 26
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Phase 2: Number of participants with adverse events and clinically significant changes in laboratory parameters, and vital signs to support identification of the RP3D
Időkeret: Up to 26 Weeks
|
Up to 26 Weeks
|
|
|
Phase 2: Plasma concentrations of momelotinib and metabolite of momelotinib 21 (M21) to support identification of the RP3D
Időkeret: Up to 26 Weeks
|
Up to 26 Weeks
|
|
|
Number of participants with adverse events (AEs) and Serious adverse events (SAEs)
Időkeret: Up to Week 108
|
Up to Week 108
|
|
|
Number of participants with adverse events (AEs) and Serious adverse events (SAEs) by severity
Időkeret: Up to Week 108
|
Up to Week 108
|
|
|
Number of participants with AEs leading to discontinuation or dose modifications
Időkeret: Up to Week 108
|
Up to Week 108
|
|
|
Plasma concentration of momelotinib and M21
Időkeret: Up to 26 Weeks
|
Up to 26 Weeks
|
|
|
Phase 2: Percentage of participants with partial response (PR) or complete response (CR) at Week 26
Időkeret: At Week 26
|
Percentage of participants with PR or CR at Week 26 to support identification of the Recommended Phase 3 dose (RP3D) |
At Week 26
|
|
Number of flare-free days
Időkeret: Up to 26 Weeks
|
Flare-free days are calendar days without clinical evidence of VEXAS flare and without treatment escalation. Total number of flare-free days is defined as the cumulative number of consecutive and non-consecutive flare-free days. |
Up to 26 Weeks
|
|
Duration of response (DoR)
Időkeret: Up to 104 Weeks
|
DoR defined as the date of clinical response (CR or PR) to the date of relapse. |
Up to 104 Weeks
|
|
Number of flare-free days with glucocorticoid (GC) dose <=10 mg/day
Időkeret: Up to 104 Weeks
|
Flare-free days are calendar days without clinical evidence of VEXAS flare and without treatment escalation. Total number of flare-free days is defined as the cumulative number of consecutive and non-consecutive flare-free days. |
Up to 104 Weeks
|
|
Percentage of participants achieving complete and partial biochemical response
Időkeret: Up to 26 Weeks
|
Complete biological response is defined as complete or partial normalization of C-reactive protein. |
Up to 26 Weeks
|
|
Objective response rate (ORR) at Week 52
Időkeret: At Week 52
|
ORR is defined as the proportion of participants who have achieved complete response or partial response |
At Week 52
|
|
Number of Participants with Hematologic Improvement- Erythroid (HI-E) response per International Working Group (IWG) 2018 criteria
Időkeret: Up to 26 Weeks
|
HI-E response is measured based on the combined incidence of: Low transfusion burden participants defined as absence of any transfusion for greater than or equal to (>=)8 consecutive weeks. High transfusion burden participants: minor response defined as reduction by >=50% of red blood cell (RBC) units for >=8 consecutive weeks. Major response defined as absence of RBC transfusions for >=8 consecutive weeks or longer up to 26 weeks. |
Up to 26 Weeks
|
|
Change from Baseline in Short Form 36 (SF-36) domain and summary scores
Időkeret: Baseline and up to Week 48
|
Short-Form 36 is a health-related survey that assesses quality of life covering 8 domains: vitality; physical functioning; bodily pain; general health perceptions; physical role functioning; emotional role functioning; social role functioning; and mental health. The domain scores are weighted to a scale ranging between 0 to 100, where higher score represents better health. The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores are derived from the eight domain scores. These scores are standardized to a general U.S. population average of 50, with a standard deviation of 10. For both PCS and MCS, scores range from 0 to 100, higher scores indicate a better health outcome. |
Baseline and up to Week 48
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Item Library (EORTC IL) 479 score
Időkeret: Baseline and up to Week 156
|
The EORTC Item Library is a database containing >1000 individual items from more than 70 EORTC quality of life measures. A subset of 7 items from the library were selected based on symptoms experienced by participants with VEXAS syndrome. Scores range from 1 to 100 with higher scores representing a higher ("worse") level of symptoms. |
Baseline and up to Week 156
|
|
Change From Baseline in Patient Reported Outcome Measurement Information System (PROMIS) Physical Function Short Form 10b
Időkeret: Baseline and up to Week 156
|
PROMIS Physical Function Short Form 10b consists of 10 questions; each with a 5-point response. PROMIS short form assesses self-reported capability of a participant rather than actual performance of physical activities. Higher scores indicate better functioning. Total possible range of scores is 10 to 50, with higher scores corresponding to a greater physical function ability. |
Baseline and up to Week 156
|
|
Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-FATIGUE)
Időkeret: Baseline and up to Week 156
|
The FACIT-Fatigue is a short, 13-item questionnaire that assesses self-reported fatigue and its associated impact on daily activities over the past 7 days. A higher score indicates a better outcome (no fatigue). The total score ranges from 0 to 52, with 0 being the worst possible score and 52 being the best possible score (indicating no fatigue). |
Baseline and up to Week 156
|
|
Changes from Baseline in Patient Global Impression of Severity (PGIS) scores
Időkeret: Baseline and up to Week 156
|
The PGIS is a single global question which asks participants to rate the severity of their VEXAS syndrome symptoms on a 5-point rating scale with response categories of "No symptoms", "Mild", "Moderate", "Severe", and "Very Severe." The PGIS scores ranges from 0 (absent) to 4 (very severe). |
Baseline and up to Week 156
|
|
Changes in Patient Global Impression of Change (PGIC) scores
Időkeret: Baseline and up to Week 156
|
The PGIC is a single global question which asks participants to rate the change in severity of their VEXAS syndrome symptoms since starting study medication using a 5-point rating scale with response categories of "much better", "a little better", "no change", "a little worse", "much worse". The PGIC score ranges from +2 (much better) to -2 (much worse). |
Baseline and up to Week 156
|
|
Changes from Baseline in European quality of life 5 dimensions 5 level version (EQ-5D-5L)
Időkeret: Baseline and up to Week 48
|
EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by 5-point Likert scale ranging from 1=no problems to 5=extreme problems. |
Baseline and up to Week 48
|
|
Changes from Baseline in European quality of life-Visual Analogue Scale (EQ-VAS)
Időkeret: Baseline and up to Week 48
|
The EQ-VAS records the respondents self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health. |
Baseline and up to Week 48
|
|
Overall Survival
Időkeret: At Months 12, 24 and 36
|
Overall survival is defined as the time from randomization to the date of death due to any cause. |
At Months 12, 24 and 36
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi igazgató: GSK Clinical Trials, GlaxoSmithKline
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 223401
- 2025-524416-11-00 (Egyéb azonosító: EU CT Number)
- 2025-524416-11-00 (Registry Identifier: CTIS (EU))
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .